Abstract
Atazanavir-ritonavir concentrations change over time during pregnancy in HIV-positive patients; the impact of genetic variants is unknown. Twenty patients were enrolled in this study; plasma and intracellular concentrations of antiretrovirals were measured, in addition to single-nucleotide polymorphisms in transport-related genes. Linear logistic regression showed that genetic variants in organic-anion-transporter-1B1- and pregnane-X-receptor-encoding genes affected third-trimester atazanavir exposure. In this prospective study, genetic variants partially explained the observed interpatient variability in third-trimester exposure to antiretrovirals.
Keywords:
HIV; antiretroviral agents; antiviral pharmacology.
Copyright © 2018 American Society for Microbiology.
MeSH terms
-
Adult
-
Atazanavir Sulfate / blood
-
Atazanavir Sulfate / pharmacokinetics*
-
Atazanavir Sulfate / therapeutic use*
-
Drug Administration Schedule
-
Drug Therapy, Combination
-
Female
-
HIV Infections / drug therapy*
-
HIV Protease Inhibitors / blood
-
HIV Protease Inhibitors / pharmacokinetics
-
HIV Protease Inhibitors / therapeutic use*
-
Humans
-
Liver-Specific Organic Anion Transporter 1 / genetics*
-
Polymorphism, Single Nucleotide / genetics
-
Pregnancy
-
Pregnancy Complications, Infectious / drug therapy
-
Pregnancy Trimester, Third
-
Pregnane X Receptor / genetics*
-
Prospective Studies
-
Ritonavir / blood
-
Ritonavir / pharmacokinetics*
-
Ritonavir / therapeutic use*
Substances
-
HIV Protease Inhibitors
-
Liver-Specific Organic Anion Transporter 1
-
NR1I2 protein, human
-
Pregnane X Receptor
-
SLCO1B1 protein, human
-
Atazanavir Sulfate
-
Ritonavir